Last updated on January 2020

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

Brief description of study

This study aims to investigate the safety and efficacy of sintilimab combined with platinum-based chemotherapy in neoadjuvant treatment of potentially resectable esophageal cancer.

Detailed Study Description

This study was designed as an open-lable, single-arm, exploratory clinical study. Sintilimab in combination with liposome paclitaxel, cis-platinum and S-1 will be given every 3 weeks to our patients for 2 cycles as neoadjuvant therapy. A radical dissection is scheduled within 6 weeks after last neoadjuvant treatment. This study will be devided for 3 phases: safety run-in, efficacy pilot and efficacy confirmation.

Clinical Study Identifier: NCT03946969

Find a site near you

Start Over